The Three Pillars of Cardiovascular Advancement
How technology, innovation, and preventive care drove the last 10 years of improved public heart health.
Related Articles
Discussing New Phase 3 Data on Nemolizumab for Prurigo Nodlaris, with Sonja Ständer, MD
This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with…
FDA Approves First Generic of Rivaroxaban (Xarelto) for CAD, PAD
The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.
Tirbanibulin Reduces Actinic Keratosis Lesions, Achieves High Patient Satisfaction
Combined analysis of data from a pair of post-registrational studies demonstrate the clinical profile and patient opinion on treatment with tirbanulin.
Risks, Benefits of Current Food Allergy Therapies, with Aikaterini Anagnostou, MD, PhD
HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.
American Academy of Dermatology
Coverage of the American Academy of Dermatology’s annual meeting. Disclaimer: This content was developed independently and is not endorsed by the American Academy of Dermatology.
When an Allergist Should Refer Endoscopic Sinus Surgery for Chronic Rhinosinusitis, with Kent Lam, MD
HCPLive spoke with Lam at AAAAI about how allergists should establish endoscopic sinus surgery expectations with patients regarding risks and benefits ahead of the operation.
FDA Approves Revakinagene Taroretcel (ENCELTO) for MacTel
With this historic approval, revakinagene taroretcel (ENCELTO) becomes the first and only FDA-approved treatment for MacTel.
When to Test for Insect Sting Allergies, with David Golden, MD
HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.
Key Questions About the Skin of Color Society’s Efforts This Year, with Crystal Aguh, MD
In this interview, Aguh answers several key questions about the efforts of the Skin of Color Society and improving diversity in clinical research.
FDA Approves Furosemide (Furoscix) for Edema in CKD
The FDA approved the sNDA for furosemide (Furoscix) to expand the indication to include treatment of edema in patients with CKD.